CDK4 and breast cancer: In comparison, our MCF7-LTED and T47D-LTED breast cancer cell models represent acquired endocrine resistant breast cancer that are intrinsically resistant to CDK4/6 inhibitors, which comprises about 20% of breast cancer patients in the clinic (9).